Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial

PURPOSE: To confirm the efficacy and safety of a novel ophthalmic cyclosporine A gel (CyclAGel, 0.05% CsA) in treating patients with moderate-to-severe dry eye disease (DED). PATIENTS AND METHODS: The COSMO trial was a randomized, multicenter, double-masked, vehicle-controlled, phase III trial. Pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Wenyan, Jiang, Xiuying, Zhu, Lei, Li, Xiaofeng, Zhou, Qizhi, Jie, Ying, You, Zhipeng, Wu, Miaoqin, Jin, Xiuming, Li, Xiaoyi, Zhou, Shiyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509011/
https://www.ncbi.nlm.nih.gov/pubmed/36164414
http://dx.doi.org/10.2147/DDDT.S370559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509011/
https://www.ncbi.nlm.nih.gov/pubmed/36164414
http://dx.doi.org/10.2147/DDDT.S370559

Ejemplares similares